Thursday, December 14, 2017 7:52:44 PM
Ha ...no I'm not going to listen to the webcast again ...
But I will challenge you on the following .
The combination of lowering surrogate risk markers like LDL cholesterol , TG's , lowering ALT/AST as well as lowering Liver fat and possibly reversing Liver Fibrosis with no pruritus ( itching ) ...is very appealing from a patient pt of view .....of which I am one .
I don't know of a better drug in development that improves all the issues noted above.
Do you ?
ENTA's NASH program ..elevation in ALT/AST ...no benefit in lowering TG or LDL
ICPT program ...need to add statins to control increase in LDL and significant pruritus at higher doses
ALL the FXR agonist programs have problems as far as I'm concerned .
So consider MDCO ...you get about the same LDL cholesterol lowering as MGL-3196 but none of the reduction of Liver fat or the same reduction in TG's.
By the way ..high TG levels is correlated with amputation in diabetics ...so another group of patients that could possibly benefit from MGL-3196
As a He FH patient with borderline dangerously high ALT levels on max dose Statins already ...the FXR agonist drugs for NASH are a no go for me .
Pt of this post .
I'm seeing a lot of patients that can benefit from MDGL's MGL-3196 .
Am I missing something here .
Whats the downside ...besides the 36 wk data not confirming the 12 wk data .
Appreciate opposing pts of view
Kiwi
But I will challenge you on the following .
The combination of lowering surrogate risk markers like LDL cholesterol , TG's , lowering ALT/AST as well as lowering Liver fat and possibly reversing Liver Fibrosis with no pruritus ( itching ) ...is very appealing from a patient pt of view .....of which I am one .
I don't know of a better drug in development that improves all the issues noted above.
Do you ?
ENTA's NASH program ..elevation in ALT/AST ...no benefit in lowering TG or LDL
ICPT program ...need to add statins to control increase in LDL and significant pruritus at higher doses
ALL the FXR agonist programs have problems as far as I'm concerned .
So consider MDCO ...you get about the same LDL cholesterol lowering as MGL-3196 but none of the reduction of Liver fat or the same reduction in TG's.
By the way ..high TG levels is correlated with amputation in diabetics ...so another group of patients that could possibly benefit from MGL-3196
As a He FH patient with borderline dangerously high ALT levels on max dose Statins already ...the FXR agonist drugs for NASH are a no go for me .
Pt of this post .
I'm seeing a lot of patients that can benefit from MDGL's MGL-3196 .
Am I missing something here .
Whats the downside ...besides the 36 wk data not confirming the 12 wk data .
Appreciate opposing pts of view
Kiwi
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
